Esketamine nasal spray: New hope for resistant depression

On March 05, 2019 The U.S. Food and Drug Administration approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepresant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression). Because of the risk […]